Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer Disease 2 Clear all
Active, not recruiting Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

NCT04437511
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Early Phase 1 Interventional

Brain Imaging in the Diabetes Prevention Program Outcomes Study

NCT03757910
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 11C-PIB
Drug
Lead sponsor
José A. Luchsinger
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease

NCT01254773
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Experimental Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Tucson, Arizona • La Habra, California • Lomita, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease

NCT03823404
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388 capsule, Placebo capsule
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
58
States / cities
Phoenix, Arizona • Sun City, Arizona • Costa Mesa, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting Phase 1 Interventional

A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

NCT06372821
View directory record Official record
Conditions
Alzheimer Disease, Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder), Autosomal Dominant Alzheimer Disease Due to Mutation of Amyloid Precursor Protein (Disorder)
Interventions
NIO752, Placebo
Drug · Other
Lead sponsor
University College, London
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Make Better Choices 2 for Rural Appalachians

NCT04309461
View directory record Official record
Conditions
Health Behavior
Interventions
Stress Management Control, Adapted MBC2 Program
Behavioral
Lead sponsor
Nancy Schoenberg
Other
Eligibility
18 Years to 100 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Benham, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Version 2 of the Smoking Cessation Smartphone App "Smiling Instead of Smoking" (SiS)

NCT03951766
View directory record Official record
Conditions
Smoking Cessation, Smoking, Tobacco
Interventions
Smiling Instead of Smoking (SiS) App Version 2
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Not applicable Interventional Results available

Hearing Aid and Individuals With Cognitive Disorders

NCT04049643
View directory record Official record
Conditions
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions
Audiologist-based fitting, Service-only Fitting, Device-only fitting
Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 2 Interventional

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil

NCT00672945
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PRX-03140, Placebo
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • National City, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Jun 10, 2026, 2:13 PM EDT
Active, not recruiting Phase 2 Interventional

Preventing Medication Mismanagement in People Living with Dementia Through Automated Medication Dispensing with Facial Recognition and Video Observation

NCT06691256
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
Interventions
HiDO-ALZ
Device
Lead sponsor
HiDO Technologies
Industry
Eligibility
65 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

NCT05462106
View directory record Official record
Conditions
Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b
Biological
Lead sponsor
AC Immune SA
Industry
Eligibility
35 Years to 85 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
13
States / cities
Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Active, not recruiting Not applicable Interventional

Brain Boosters 2 in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention

NCT05027789
View directory record Official record
Conditions
Memory Disorders, Cognitive Impairment
Interventions
Self-Guided, Structured Group
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
65 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

S-Equol in Alzheimer's Disease 2 Trial

NCT03101085
View directory record Official record
Conditions
Alzheimer Disease
Interventions
S-equol and Placebo, Placebo and S-equol
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

NCT04971733
View directory record Official record
Conditions
Alzheimer Disease
Interventions
E2814
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
La Jolla, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients

NCT06432166
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
2-hydroxybenzylamine acetate, Placebo
Drug · Other
Lead sponsor
MTI Biotech Inc
Industry
Eligibility
55 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jun 10, 2026, 2:13 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
7
States / cities
New Haven, Connecticut • Chicago, Illinois • Elk Grove Village, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jun 10, 2026, 2:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia

NCT00178568
View directory record Official record
Conditions
Sleep Disorders
Interventions
Stress Management and Healthy Sleep Practices
Behavioral
Lead sponsor
Kathy Kennedy
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional Results available

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT02292186
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jun 10, 2026, 2:13 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Jun 10, 2026, 2:13 PM EDT
Recruiting Phase 2 Interventional

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

NCT07033494
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
MK-2214, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
36
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 10, 2026, 2:13 PM EDT
Completed Phase 2 Interventional

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

NCT00099710
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Curcumin C3 Complex
Dietary Supplement
Lead sponsor
John Douglas French Foundation
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Jun 10, 2026, 2:13 PM EDT